RIGL logo

Rigel Pharmaceuticals Inc. (New)

RIGL

RIGL: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

more

Show RIGL Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of RIGL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RIGL's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $10,000 Jul 16, 2021 Issue: Health Issues
  • $20,000 Jul 16, 2021 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Tyrosine kinase inhibitors Jun. 13, 2023
  • Patent Title: Compositions and methods for inhibition of the jak pathway Jun. 06, 2023
  • Patent Title: Rip1k inhibitors Jun. 06, 2023
  • Patent Title: Rip1k inhibitors Feb. 21, 2023
  • Patent Title: Heterocyclic rip1 inhibitory compounds Feb. 14, 2023
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jan. 31, 2023
  • Patent Title: Amide compounds and method for making and using Dec. 20, 2022
  • Patent Title: 2,4-diamino-pyrimidine compounds and method for making and using the compounds Dec. 13, 2022
  • Patent Title: Irak inhibitors and method for making and using Nov. 08, 2022
  • Patent Title: Heterocyclic rip1 kinase inhibitors Oct. 25, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Oct. 18, 2022
  • Patent Title: Tgf-β inhibitors Oct. 11, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Aug. 09, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jul. 05, 2022
  • Patent Title: Pyrazole compounds and methods for making and using the compounds Jun. 28, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jun. 28, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jun. 28, 2022
  • Patent Title: Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations Jun. 28, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same May. 17, 2022
  • Patent Title: Benzazole compounds and methods for making and using the compounds Apr. 12, 2022
  • Patent Title: Nrf2 activating compounds and uses thereof Mar. 22, 2022
  • Patent Title: Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds Jan. 25, 2022
  • Patent Title: Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan. 25, 2022
  • Patent Title: Compounds and method for treating autoimmune diseases Jan. 11, 2022
  • Patent Title: Compositions and methods for inhibition of the jak pathway Dec. 14, 2021
  • Patent Title: Compositions and methods for inhibition of the jak pathway Nov. 16, 2021
  • Patent Title: Direct ampk activators Nov. 16, 2021
  • Patent Title: Fumarate analogs and uses thereof Sep. 28, 2021
  • Patent Title: Tyrosine kinase inhibitors Sep. 07, 2021
  • Patent Title: Acvr2a-specific antibody and method of treatment of muscle atrophy Aug. 31, 2021
  • Patent Title: Kinase inhibitors and methods for making and using Jul. 13, 2021
  • Patent Title: Tgf-ß inhibitors Jun. 01, 2021
  • Patent Title: 2,4-pyrimidinediamine compounds and their uses May. 18, 2021
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Apr. 13, 2021
  • Patent Title: Amide compounds and method for making and using Mar. 16, 2021
  • Patent Title: Irak inhibitors and method for making and using Mar. 09, 2021
  • Patent Title: Ampk-activating heterocyclic compounds and methods for using the same Mar. 09, 2021
  • Patent Title: Nrf2 activating compounds and uses thereof Mar. 09, 2021
  • Patent Title: Prodrugs of nrf2 activating compounds and uses thereof Jan. 12, 2021
  • Patent Title: 2,3-disubstituted pyridine compounds as tgf-β inhibitors and methods of use Dec. 08, 2020
  • Patent Title: Tyrosine kinase inhibitors Dec. 01, 2020
  • Patent Title: Nrf2 activating compounds and uses thereof Nov. 24, 2020
  • Patent Title: Tgf-β inhibitorc Nov. 03, 2020
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Oct. 27, 2020
  • Patent Title: Protein kinase c inhibitors and uses thereof Oct. 06, 2020
  • Patent Title: Benzazole compounds and methods for making and using the compounds Sep. 15, 2020
  • Patent Title: Prodrugs of nrf2 activating compounds and uses thereof Sep. 15, 2020
  • Patent Title: Antigen binding molecules to tigit Sep. 01, 2020
  • Patent Title: 2,4-pyrimidinediamine compounds and their uses Jul. 14, 2020
  • Patent Title: 2,4-diamino-pyrimidine compounds and method for making and using the compounds Jul. 14, 2020
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of RIGL in WallStreetBets Daily Discussion

RIGL News

Recent insights relating to RIGL

CNBC Recommendations

Recent picks made for RIGL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RIGL

Corporate Flights

Flights by private jets registered to RIGL